Integrative Biomedical Research
Integrative Biomedical Research (Journal of Angiotherapy) | Online ISSN 3068-6326
685
Citations
1.4m
Views
733
Articles
Volume 10 Number 1 2026
CASE STUDY (Open Access)
Serum Uric Acid Reduction Following Use of Canssu5®, a Standardized Orthosiphon stamineus Extract, in Adults with Hyperuricemia: A Retrospective Case Study
Aman Shah Abdul Majid 1*
Integrative Biomedical Research 10 (1) 1-11 https://doi.org/10.25163/biomedical.10110722
Submitted: 31 January 2026 Revised: 31 March 2026 Accepted: 04 April 2026 Published: 06 April 2026
Abstract
Background: Hyperuricemia remains a central biochemical driver of gout and is increasingly implicated in broader cardiometabolic and renal disorders. Although pharmacologic urate-lowering therapies are effective, their use is sometimes constrained by intolerance, adherence challenges, or patient preference for alternative approaches. In this context, botanically derived compounds with multi-target activity have begun to attract interest, though clinical evidence remains limited.
Methods: This retrospective case series evaluated ten adults with laboratory-confirmed hyperuricemia who consumed Canssu5®, a standardized Orthosiphon stamineus extract, under real-world conditions. Serum uric acid (SUA) values obtained from accredited laboratories before and after supplementation were analyzed using paired-sample statistical methods. Individual-level responses, percentage reductions, and achievement of clinically relevant SUA thresholds were examined descriptively.
Results: All participants demonstrated reductions in SUA following product use (Table 1; Figure 1). Mean SUA declined from 0.592 ± 0.091 mmol/L to 0.364 ± 0.059 mmol/L, corresponding to a mean reduction of 0.228 mmol/L (37.4%). The change was statistically significant (t(9) = 7.78, p < 0.001), with a large effect size (Cohen’s d ≈ 2.46). Seventy percent of participants achieved post-treatment SUA levels below 0.40 mmol/L. No adverse events were reported.
Conclusion: Use of a standardized Orthosiphon stamineus extract was associated with consistent reductions in serum uric acid across all cases. While the findings are encouraging, the retrospective design and small sample size limit causal interpretation. These observations should be considered preliminary and warrant confirmation in controlled clinical trials.
Keywords: Hyperuricemia; Gout; Orthosiphon stamineus; Rosmarinic acid; Botanical therapeutics
References
Akowuah, G. A., Zhari, I., Norhayati, I., & Sadikun, A. (2004). Effect of extraction temperature on flavonoid and phenolic contents of Orthosiphon stamineus leaves. Journal of Tropical Medicinal Plants, 5(1), 49–54.
Al-Dhabi, N. A., Arasu, M. V., Park, C. H., & Park, S. U. (2020). An up-to-date review of rutin and its biological and pharmacological activities. Biomedicine & Pharmacotherapy, 131, 110657. https://doi.org/10.1016/j.biopha.2020.110657
Ameer, O. Z., Salman, I. M., Asmawi, M. Z., Ibraheem, Z. O., & Yam, M. F. (2012). Orthosiphon stamineus: Traditional uses, phytochemistry, pharmacology, and toxicology. Journal of Medicinal Food, 15(8), 678–690. https://doi.org/10.1089/jmf.2011.1973
Becker, M. A., & Jolly, M. (2006). Clinical gout and the pathogenesis of hyperuricemia. Rheumatic Disease Clinics of North America, 32(2), 275–293. https://doi.org/10.1016/j.rdc.2006.02.004
Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., Tsioufis, C., & Hyperuricaemia and Gout Working Group of the European Society of Hypertension. (2014). Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European Journal of Internal Medicine, 25(5), 372–381. https://doi.org/10.1016/j.ejim.2014.01.012
Cos, P., Ying, L., Calomme, M., Hu, J. P., Cimanga, K., Van Poel, B., Pieters, L., Vlietinck, A. J., & Vanden Berghe, D. (1998). Structure–activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers. Journal of Natural Products, 61(1), 71–76. https://doi.org/10.1021/np970237h
Dalbeth, N., Merriman, T. R., & Stamp, L. K. (2016). Gout. The Lancet, 388(10055), 2039–2052. https://doi.org/10.1016/S0140-6736(16)00346-9
Damsud, T., Adisakwattana, S., & Phuwapraisirisan, P. (2014). Three new phenylbutanoid glycosides from the leaves of Orthosiphon stamineus. Journal of Natural Medicines, 68(3), 563–567. https://doi.org/10.1007/s11418-014-0823-2
Johnson, R. J., Nakagawa, T., Jalal, D., Sánchez-Lozada, L. G., Kang, D. H., & Ritz, E. (2013). Uric acid and chronic kidney disease: Which is chasing which? Nephrology Dialysis Transplantation, 28(9), 2221–2228. https://doi.org/10.1093/ndt/gft029
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., Kaldas, M., Gogia, M., Perez-Ruiz, F., Taylor, W., Lioté, F., Choi, H., Singh, J. A., Dalbeth, N., Kaplan, S., … Mandell, B. (2012). 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research, 64(10), 1431–1446. https://doi.org/10.1002/acr.21772
Kong, L. D., Cai, Y., Huang, W. W., Cheng, C. H. K., & Tan, R. X. (2000). Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. Journal of Ethnopharmacology, 73(1–2), 199–207. https://doi.org/10.1016/S0378-8741(00)00295-6
Lin, C. M., Chen, C. S., Chen, C. T., Liang, Y. C., & Lin, J. K. (2002). Molecular modeling of flavonoids that inhibits xanthine oxidase. Biochemical and Biophysical Research Communications, 294(1), 167–172. https://doi.org/10.1016/S0006-291X(02)00442-4
Pacher, P., Nivorozhkin, A., & Szabó, C. (2006). Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacological Reviews, 58(1), 87–114. https://doi.org/10.1124/pr.58.1.6
Petersen, M., & Simmonds, M. S. J. (2003). Rosmarinic acid. Phytochemistry, 62(2), 121–125. https://doi.org/10.1016/S0031-9422(02)00513-7
Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., Lioté, F., Mallen, C., Nuki, G., Perez-Ruiz, F., Pimentao, J., Punzi, L., Pywell, A., So, A., Tausche, A. K., … Bardin, T. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 76(1), 29–42. https://doi.org/10.1136/annrheumdis-2016-209707
Sriplang, K., Adisakwattana, S., Rungsipipat, A., & Yibchok-Anun, S. (2007). Effects of Orthosiphon stamineus aqueous extract on plasma glucose concentration and lipid profile in normal and streptozotocin-induced diabetic rats. Journal of Ethnopharmacology, 109(3), 510–514. https://doi.org/10.1016/j.jep.2006.08.027
Stamp, L. K., & Chapman, P. T. (2013). Gout and its comorbidities: Implications for therapy. Rheumatology, 52(1), 34–44. https://doi.org/10.1093/rheumatology/kes211
Yam, M. F., Ang, L. F., Basir, R., Salman, I. M., Ameer, O. Z., Asmawi, M. Z., & Ahmad, M. (2009). Evaluation of the anti-inflammatory and analgesic activities of Orthosiphon stamineus Benth standardized extract. Journal of Ethnopharmacology, 122(2), 305–311. https://doi.org/10.1016/j.jep.2008.12.023
Recommended articles
Lanctos 75™ is A Novel Retino-Protective and Neovascular Inhibitor for Diabetic Retinopathy
Investigation Of Anti-Tumour Activity Of Orthosiphon Stamineus On Human Oral Squamous Cell Carcinoma
Anti-tumor Activity of NuvastaticTM (C5OSEW5050ESA) of Orthosiphon stamineus and Rosmarinic Acid in An Athymic Nude Mice Model of Breast Cancer
1
Save
Save
0
Citation
Citation
18
View
View
0
Share
Share